ClaimHit for IP Brokers

Evidence of use, before the buyer asks

A portfolio sells on demonstrated relevance. ClaimHit screens each asset against the live market, ranks what it finds by how strong the evidence actually is, and gives you charts you can put in the data room.

Apply for Beta Access →See how a chart is built →
What makes a package hard to build
Evidence of use is the first question a buyer asks and the most expensive thing to produce.
Screening a whole portfolio manually is not viable, so assets get sold on claim language alone.
A list of company names without sources invites the buyer to discount everything on it.

What ClaimHit does about it

📦

Screen the portfolio, not one patent

Upload a batch and let each asset run through the same pipeline. Assets with live, evidenced targets separate themselves from the ones that do not.

⚖️

Ranked by what was proven

Results are sorted by what could actually be verified — confirmed on a manufacturer's own page, or agreed by the models but unconfirmed. The distinction is stated, not blurred.

📋

Charts for the data room

Element-by-element Hit Charts with the evidence behind every limitation — the artefact a buyer's counsel will actually read.

🌐

The long tail counts

Beyond the obvious names: component distributors, regulatory records, software catalogues and marketplaces are searched by field, so mid-market practitioners surface too.

✓ Every result has to earn it

Candidates come from several models, live web and neural search, forward citations, and the authoritative registries for the field — but breadth only widens the net. Each one is still checked against real, citable evidence, and anything that cannot be evidenced is dropped rather than shown with a caveat. See every source →

Run one asset you have already sold, and compare what comes back to what you found by hand.

Apply for Beta Access →
ClaimHit is also used by (see all →)